Ireland
--:--IST
Starting soon Not applicable

ZeroOCD: Learn to Overcome Contamination OCD With Your Smartphone

NCT07194473 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2025-09-21
Last updated
2025-09-26

Condition(s) studied

Obsessive Compulsive Disorder (OCD)

Investigational drug(s) / intervention(s)

ZeroOCDVideoconferencing CBT

ZeroOCD: The ZeroOCD app contains the following components: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention

Videoconferencing CBT: Videoconferencing CBT contains the following chapters: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention

Study summary

This study is a three-arm randomized controlled trial designed to evaluate the efficacy of a smartphone-based augmented reality (AR) cognitive behavioral therapy (CBT) app, called ZeroOCD, for individuals with elevated contamination-related obsessive-compulsive disorder (OCD) symptoms. The AR-CBT app will be compared to both an active control condition (manualized CBT via videoconferencing) and a waitlist control group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: * • OCD symptoms, mean score \> 7 on the Yale Brown Obsessive Compulsive Scale (Y-BOCS) * Fear of contamination OCD symptoms, mean score \> 6 on the Padua Inventory contamination fear subscale (PI) * Having access to a compatible smartphone * Having an internet connection * Proficiency in one of the countries' languages (i.e., Dutch/ Flemish, German, or Swedish) * Willing to participate in the research study and provide informed consent Exclusion Criteria: * • Having been diagnosed with bipolar or psychotic disorder (self-report) * Severe depressive symptoms (Patient Health Questionnaire, PHQ-9, score \> 20) * Reporting suicidality (PHQ-9, item 9 \> 2 points at screening) * Fear of contamination due to disorder other than OCD (clinical judgment based on results from the Yale Brown Obsessive Compulsive Scale, Y-BOCS, Generalized Anxiety Disorder-7 items, GAD-7, Short Health Anxiety Inventory, SHAI) * Parallel psychological treatment * Non-stable dosage of psychoactive medication during the last three months or planned changes during the study period.

Primary outcome measure(s)

  • OCD Symptoms (Interview) — At baseline, At 10 weeks, At 20 weeks (only WL condition) At 24 weeks
    Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Change from baseline in the observer-rated severity of OCD symptoms. This is a 10-item, clinician-rated scale that provides separate subtotals for the severity of obsessions and compulsions. Total scores range from 0 to 40, with higher scores indicating more severe symptoms. The Y-BOCS is also used for the eligibility (mean score \> 7).

Trial sites (4)

FacilityCityRegionStatus
Thomas More Mechelen Mechelen Belgium
Vrije Universiteit Amsterdam Amsterdam North Holland
Stockholm University Stockholm Sweden
UBERN Bern Switzerland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07194473 on ClinicalTrials.gov ↗ ← All trials in the Netherlands